Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM).

Frasch CE, Preziosi MP, LaForce FM.

Hum Vaccin Immunother. 2012 Jun;8(6):715-24. doi: 10.4161/hv.19619. Epub 2012 Apr 12. Review.

PMID:
22495119
2.

The Meningitis Vaccine Project.

LaForce FM, Konde K, Viviani S, Préziosi MP.

Vaccine. 2007 Sep 3;25 Suppl 1:A97-100. Epub 2007 May 7.

PMID:
17521780
3.

Emergence of serogroup X meningococcal disease in Africa: need for a vaccine.

Xie O, Pollard AJ, Mueller JE, Norheim G.

Vaccine. 2013 Jun 12;31(27):2852-61. doi: 10.1016/j.vaccine.2013.04.036. Epub 2013 Apr 24. Review.

PMID:
23623866
4.

[Meningococcal meningitis epidemics in sub-Saharan Africa and the meningococcal A conjugate vaccine].

Nicolas P.

Med Sante Trop. 2012 Jul-Sep;22(3):246-58. doi: 10.1684/mst.2012.0086. French.

5.

Technical Development of a New Meningococcal Conjugate Vaccine.

Frasch CE, Kapre SV, Lee CH, Préaud JM.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S404-9. doi: 10.1093/cid/civ595. Review.

6.

Evaluation of serogroup A meningococcal vaccines in Africa: a demonstration project.

Soriano-Gabarró M, Rosenstein N, LaForce FM.

J Health Popul Nutr. 2004 Sep;22(3):275-85.

PMID:
15609780
7.

From Epidemic Meningitis Vaccines for Africa to the Meningitis Vaccine Project.

Aguado MT, Jodar L, Granoff D, Rabinovich R, Ceccarini C, Perkin GW.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S391-5. doi: 10.1093/cid/civ593. Review.

8.

Serogroup A meningococcal conjugate vaccines in Africa.

Kristiansen PA, Jørgensen HJ, Caugant DA.

Expert Rev Vaccines. 2015;14(11):1441-58. doi: 10.1586/14760584.2015.1084232. Epub 2015 Aug 31. Review.

PMID:
26358167
9.

Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines.

Mueller JE, Borrow R, Gessner BD.

Expert Rev Vaccines. 2006 Jun;5(3):319-36. Review.

PMID:
16827617
10.

Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data.

Novak RT, Kambou JL, Diomandé FV, Tarbangdo TF, Ouédraogo-Traoré R, Sangaré L, Lingani C, Martin SW, Hatcher C, Mayer LW, Laforce FM, Avokey F, Djingarey MH, Messonnier NE, Tiendrébéogo SR, Clark TA.

Lancet Infect Dis. 2012 Oct;12(10):757-64. doi: 10.1016/S1473-3099(12)70168-8. Epub 2012 Jul 18.

11.

Impact of MenAfriVac in nine countries of the African meningitis belt, 2010-15: an analysis of surveillance data.

Trotter CL, Lingani C, Fernandez K, Cooper LV, Bita A, Tevi-Benissan C, Ronveaux O, Préziosi MP, Stuart JM.

Lancet Infect Dis. 2017 Aug;17(8):867-872. doi: 10.1016/S1473-3099(17)30301-8. Epub 2017 May 22.

PMID:
28545721
12.

Serogroup W Meningitis Outbreak at the Subdistrict Level, Burkina Faso, 2012.

Cibrelus L, Medah I, Koussoubé D, Yélbeogo D, Fernandez K, Lingani C, Djingarey M, Hugonnet S.

Emerg Infect Dis. 2015 Nov;21(11):2063-6. doi: 10.3201/eid2111.150304.

13.

Meningococcal conjugate vaccines.

Zimmer SM, Stephens DS.

Expert Opin Pharmacother. 2004 Apr;5(4):855-63. Review.

PMID:
15102568
14.

Epidemic meningitis due to Group A Neisseria meningitidis in the African meningitis belt: a persistent problem with an imminent solution.

Marc LaForce F, Ravenscroft N, Djingarey M, Viviani S.

Vaccine. 2009 Jun 24;27 Suppl 2:B13-9. doi: 10.1016/j.vaccine.2009.04.062. Epub 2009 May 27. Review.

PMID:
19477559
15.

The Evolution of the Meningitis Vaccine Project.

Tiffay K, Jodar L, Kieny MP, Socquet M, LaForce FM.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S396-403. doi: 10.1093/cid/civ594. Review.

16.

Introduction and Rollout of a New Group A Meningococcal Conjugate Vaccine (PsA-TT) in African Meningitis Belt Countries, 2010-2014.

Djingarey MH, Diomandé FV, Barry R, Kandolo D, Shirehwa F, Lingani C, Novak RT, Tevi-Benissan C, Perea W, Preziosi MP, LaForce FM.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S434-41. doi: 10.1093/cid/civ551. Review.

17.

Challenges and Opportunities While Developing a Group A Meningococcal Conjugate Vaccine Within a Product Development Partnership: A Manufacturer's Perspective From the Serum Institute of India.

Kulkarni PS, Socquet M, Jadhav SS, Kapre SV, LaForce FM, Poonawalla CS.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S483-8. doi: 10.1093/cid/civ500. Review.

18.

Conducting vaccine clinical trials in sub-Saharan Africa: operational challenges and lessons learned from the Meningitis Vaccine Project.

Marchetti E, Mazarin-Diop V, Chaumont J, Martellet L, Makadi MF, Viviani S, Kulkarni PS, Preziosi MP.

Vaccine. 2012 Nov 6;30(48):6859-63. doi: 10.1016/j.vaccine.2012.09.008. Epub 2012 Sep 16.

PMID:
22989686
19.

Meningococcal meningitis in sub-Saharan Africa: the case for mass and routine vaccination with available polysaccharide vaccines.

Robbins JB, Schneerson R, Gotschlich EC, Mohammed I, Nasidi A, Chippaux JP, Bernardino L, Maiga MA.

Bull World Health Organ. 2003;81(10):745-50; discussion 751-5. Epub 2003 Nov 25.

20.

Regulatory Pathways That Facilitated Timely Registration of a New Group A Meningococcal Conjugate Vaccine for Africa's Meningitis Belt Countries.

Dellepiane N, Akanmori BD, Gairola S, Jadhav SS, Parker C, Rodriguez C, Srivastava S.

Clin Infect Dis. 2015 Nov 15;61 Suppl 5:S428-33. doi: 10.1093/cid/civ491. Review.

Supplemental Content

Support Center